Brain Drug Delivery for the Treatment of Neurological Disorders

Touraj Ehtezazi (Editor)

ISBN: 9781032771915

Published: August 10, 2026

Format: Hardcover

Language: English

Publisher: CRC Press (Routledge)

Description

Brain Drug Delivery for the Treatment of Neurological Disorders, edited by Touraj Ehtezazi (Reader in Pharmaceutics, Liverpool John Moores University), gathers the pharmaceutical science needed to design new treatments for chronic, non-communicable neurological disorders — conditions that, unlike stroke or infectious brain disease, still lack a coordinated research and delivery framework. Fourteen chapters from an international group of contributors cover the blood-brain barrier's role in treatment resistance, physiological barriers to drug delivery, novel nanoparticle and exosome-based delivery systems, monoclonal antibody targeting, and the industrial and regulatory steps required to bring a brain-targeted therapy to market. Part of the established Drugs and the Pharmaceutical Sciences series.

Key Features

- Summarizes in vitro and in vivo evaluation methods for brain drug delivery systems, including techniques that complement imaging approaches such as IVIS.
- Surveys novel delivery platforms in active development, including nanoparticles, exosomes, and monoclonal antibodies engineered to cross the blood-brain barrier. Read our blog post on blood-brain barrier nanoparticle delivery.
- Addresses industrial-scale production and the regulatory considerations formulation scientists must plan for before a brain-targeted therapy can reach clinical use.

Coverage

- Physiological barriers that limit drug delivery to the diseased brain, and strategies to overcome them
- Novel nanoparticle and exosome-based delivery systems, and monoclonal antibody targeting of the brain
- Hematological, immunological, and cytotoxic safety evaluation of brain-targeted delivery systems
- Personalised therapies for rare neurological disorders, and industrial and regulatory considerations for scale-up

About the Editor

Touraj Ehtezazi is a Reader in Pharmaceutics at Liverpool John Moores University. He trained as a pharmacist at the University of Tabriz, Iran, earned his PhD from the University of Nottingham in 1997, and held posts at Nottingham and the University of Leicester before joining Liverpool John Moores in 2002, where his research focuses on drug delivery systems for neurological disease.

Table of Contents

1. Neurological Disorders and Their Impact
2. Physiological Barriers of Targeting the Diseased Brain
3. Poly (ADP-Ribose) Polymerase (PARP) as a Novel Therapeutic Target for Developing Treatments Against Neurological and Neurodegenerative Conditions
4. Targeting Microglia for the Treatment of the Diseased Brain
5. Novel Nanoparticles as Drug Delivery Systems to the Brain
6. Exosomes for Drug Delivery to the Brain
7. Targeting the Brain with Monoclonal Antibodies
8. In Vitro Evaluations of Drug Delivery to the Brain
9. In Vivo Evaluations of Drug Delivery to the Brain
10. Introduction to Hematological and Immunological Safety in Brain Drug Delivery
11. Cytotoxic Evaluations of the Drug Delivery Systems to the Brain
12. Personalised Therapies for Rare Neurological Disorders
13. Industrial Aspects to Be Considered for Drug Delivery for Brain
14. Regulatory Aspects to Be Considered in the Development of Drug Delivery Systems to the Brain

Why buy this book?

Non-communicable neurological disorders are rising in prevalence worldwide, yet the pharmaceutical science needed to get a therapy across the blood-brain barrier remains fragmented across journals and specialties. This volume brings formulation science, in vitro/in vivo evaluation methods, and the industrial and regulatory pathway together in one reference, making it a practical acquisition for pharmaceutical science departments, neuroscience research libraries, and drug development teams working on CNS-targeted therapies.

Browse more titles in our Medicine collection.

Keywords

brain drug delivery, blood-brain barrier, neurological disorders, nanoparticle drug delivery, exosome drug delivery, monoclonal antibodies brain, CNS pharmaceutics, Touraj Ehtezazi, drugs and the pharmaceutical sciences

Target Audience

Pharmaceutical scientists, pharmacologists, neuroscience researchers, drug delivery formulation scientists, academic and research libraries

Genre

Pharmacology, Drug Delivery, Neurology

Q&A

What is this book about?
It covers the pharmaceutical science behind delivering drugs across the blood-brain barrier to treat chronic neurological disorders, including delivery systems, evaluation methods, and the regulatory pathway to clinical use.

Who edited Brain Drug Delivery for the Treatment of Neurological Disorders?
It was edited by Touraj Ehtezazi, Reader in Pharmaceutics at Liverpool John Moores University, with contributions from an international group of pharmaceutical scientists and clinicians.

Does the book cover nanoparticle and antibody-based delivery methods?
Yes. Separate chapters cover novel nanoparticles, exosomes, and monoclonal antibodies as delivery systems designed to cross the blood-brain barrier. For more context, see our blog post on blood-brain barrier nanoparticle delivery.

Is this book useful for pharmaceutical industry and regulatory teams, not just academics?
Yes. Chapters 13 and 14 specifically address industrial-scale production and the regulatory considerations required before a brain-targeted therapy can advance to clinical use.

Where can I buy Brain Drug Delivery for the Treatment of Neurological Disorders?
You can order Brain Drug Delivery for the Treatment of Neurological Disorders directly from CLNZ Books, with worldwide shipping included and secure payment via credit card or PayPal.

📘 Learn more about shipping, delivery times, and returns, see our FAQ here

📦 New to ordering with us? See our How to Order guide for payment, shipping, and institutional order options.